Personis股价走高，此前该公司宣布与耶鲁大学癌症中心合作开展一项名为“一项单组II期试验，在激素受体阳性HER 2阴性乳腺癌中使用埃来司群进行循环肿瘤DNA引导辅助治疗有晚期复发风险（CATE）”的临床试验。"

Personalis shares are trading higher after the company announced a collaboration with the Yale Cancer Center for a clinical trial titled "A single arm phase II trial of circulating tumor DNA-guided adjuvant therapy with elacestrant in hormone receptor positive HER2 negative breast cancers at risk for late recurrence (CATE)."